Abstract
Key Points: Immunotherapy for treatment of hematological malignancies is immunosuppressive, and chronic immunosuppression is a risk factor for PML. Early diagnosis is vital for instituting prompt immune reconstitution as treatment; brain biopsy is necessary in suspicious cases.

This publication has 25 references indexed in Scilit: